Warfarin Sodium Tablets IP & BP

1. Product Introduction

Warfarin Sodium Tablets are prescription oral anticoagulants that reduce vitamin K-dependent blood clotting. The supplied product list includes IP 1 mg, 2 mg and 5 mg tablets, and BP 1 mg, 2 mg, 3 mg and 5 mg tablets. All are described as uncoated.

Warfarin has a narrow therapeutic index: too little anticoagulation can allow thrombosis, while too much can cause serious bleeding. Dose adjustments must be guided by INR testing and clinical assessment.

2. Product Specifications

Excipients: q.s. for each supplied variant. Therapeutic class: Vitamin K antagonist / oral anticoagulant. Important label check: IP entries use the term “Warfarin Sodium Clathrate” while several BP entries say “Warfarin tablets”; the active-moiety basis and any hydrate/clathrate equivalence must be checked against approved specifications. A 10 mg strength is mentioned only in general promotional copy and is not confirmed by a supplied formula. Scoring, color coding, 36-month shelf life and specific packaging are also unverified.

3. Manufacturing Technology

Low-dose warfarin tablets demand validated blending and tablet compression with careful segregation controls, because uniform active content is essential. Process validation should address blend homogeneity, potency, contamination prevention and labeling controls between strengths.

The supplied product descriptions specify uncoated tablets but do not establish that they are scored or color-coded. Do not assume a tablet can be split unless the approved product label specifically allows it. Claims of WHO-GMP certification or a particular manufacturing site require documentary verification.

4. Quality Assurance

• Identity and assay of the active ingredient using validated pharmacopoeial or approved methods.
• Content uniformity of individual low-dose tablets and appropriate batch-release testing.
• Disintegration/dissolution and physical tests according to the approved specification.
• Stability studies and packaging validation for each strength and market.
• Strength differentiation and label reconciliation to reduce medication errors.

Ingredient or finished-product IP/BP compliance must be verified against current applicable standards.

5. Therapeutic Uses and Mechanism

Warfarin inhibits vitamin K epoxide reductase (VKORC1), reducing synthesis of functional vitamin K-dependent clotting factors. Depending on indication and patient-specific factors, it may be used for prevention or treatment of venous thromboembolism (DVT/PE), stroke prevention in selected patients with atrial fibrillation, and prevention of thrombosis with certain mechanical heart valves.

Warfarin does not dissolve existing clots immediately, and it is not a blood-pressure-lowering drug. Choice of anticoagulant and treatment duration require a clinician.

6. Export and Regulatory Support

Healthy Life Pharma Pvt. Ltd. and Healthy Inc are named as manufacturer and exporter in the supplied material. Buyers should request the current manufacturing authorization, batch certificate of analysis, approved labels, stability data and market-specific registration documents.

WHO-GMP certification, COPP, Free Sale Certificate, CTD/ACTD availability, export destinations and logistics terms should be confirmed before making commercial commitments.

7. Frequently Asked Questions

Q: Which strengths are documented?
A: IP 1, 2 and 5 mg; BP 1, 2, 3 and 5 mg.

Q: Is warfarin used to treat high blood pressure?
A: No. It is an anticoagulant, not an antihypertensive.

Q: Why are INR tests required?
A: INR helps assess anticoagulant effect and guide individualized dosing.

Q: Can tablets be split?
A: Only when permitted by the approved label and directed by a clinician; scoring is not established by the supplied tablet specifications.

Q: Should patients avoid leafy greens?
A: Usually they should keep vitamin K intake reasonably consistent rather than suddenly eliminating healthy foods.

8. Dosage and Administration

Prescription-only, individualized treatment. Warfarin dose depends on the indication, target INR, current INR, age, medical conditions, diet and interacting medicines. There is no safe universal dose schedule for all patients.

Take as prescribed at a consistent time. Regular INR testing is essential, particularly when starting treatment or when medicines, illness or diet change. Never double a missed dose or stop therapy without following the treating clinician’s instructions.

9. Side Effects, Interactions and Major Warnings

Major warning: Serious or fatal bleeding can occur. Urgent medical attention is required for uncontrolled bleeding, vomiting blood, black/tarry stools, severe headache, sudden weakness, head injury or other symptoms of major bleeding.

• Pregnancy: Warfarin can cause fetal harm and is generally contraindicated during pregnancy except for rare specialist-managed situations, such as certain mechanical-valve cases.
• Drug interactions: Many antibiotics, antifungals, antiplatelet agents, NSAIDs and other drugs can alter bleeding risk or INR. Check every prescription, OTC drug and supplement.
• Diet: Keep vitamin K consumption consistent; discuss major dietary changes.
• Other risks: Skin necrosis, purple toe syndrome and other rare serious complications are possible.

Patients must receive appropriate anticoagulation counseling and INR follow-up.

10. Storage Instructions

Store according to the approved package label, protected from moisture and excessive light. The supplied product specifications do not independently verify a universal storage temperature or 36-month expiry. Keep securely out of reach of children, and retain tablets in clearly labeled packaging to prevent strength confusion.